reference/9320552

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9320552

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	534
issn	0169-5002
issueIdentifier	3
pageRange	529-534
publicationName	Lung cancer (Amsterdam, Netherlands)
startingPage	529
bibliographicCitation	Banz K, Bischoff H, Brunner M, Chouaid C, de Castro Carpeño J, de Marinis F, Grossi F, Vergnenègre A, Walzer S. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer. 2011 Dec;74(3):529–34. doi: 10.1016/j.lungcan.2011.04.010. PMID: 21592611.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8eb286de061dd2a04b925ea4deb00f77 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6f3a4782c583ad61779683ce6f3b279a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03f49cd4b9359d64429e3a2726bfbd07 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e2687355507d6e4550f6dc608c58f53a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac3059df00ab0b01f9201e32ab0c121b http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4290-5524 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89d17e78a89af820cd8eb131682a09c5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_58efd57bc1a3e22943ad5eb81adfac93 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2669939089f945c5f0959145e9c77035 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8412-3136 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c6c8ed79ee173ad09d191177ed922414 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2694-968X
date	201112
identifier	https://pubmed.ncbi.nlm.nih.gov/21592611 https://doi.org/10.1016/j.lungcan.2011.04.010
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8534 https://portal.issn.org/resource/ISSN/0169-5002
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain
discusses	http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0493669
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D002289Q000191
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005971 http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D002289Q000503 http://id.nlm.nih.gov/mesh/D011799 http://id.nlm.nih.gov/mesh/D000068437 http://id.nlm.nih.gov/mesh/D002289Q000473 http://id.nlm.nih.gov/mesh/D013030 http://id.nlm.nih.gov/mesh/D005602 http://id.nlm.nih.gov/mesh/D000069347 http://id.nlm.nih.gov/mesh/D005858 http://id.nlm.nih.gov/mesh/D007558
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176870 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127377427 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851

Total number of triples: 52.